Why SELLAS Life Sciences Group (SLS) Stock Rose 2.03% in 10 Minutes on Nov 20, 2026
MoveSurge measured three earlier SELLAS Life Sciences Group headlines with an attributed reaction between Aug 22, 2026 and Nov 19, 2026. The largest was +4.05% in 10 minutes, on Oct 28, 2026.
- SLS rose 2.03% in the 10 minutes after the 14:12:46 ET headline, from $13.55 to $13.82.
- The move kept building after the first minute: +0.46% at one minute, +2.03% at 10 minutes.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| SLS | 13.55 | 13.55 | 13.61 | 13.82 | +0.46% | +2.03% |
SELLAS Life Sciences Group (SLS) shares rose 2.03% in the 10 minutes after this headline reached the MoveSurge news feed at 14:12:46 ET on Friday, November 20, 2026: “Sellas Life Sciences says galinpepimut-S met the Phase 3 REGAL trial’s primary endpoint, reducing death risk by 41% in AML patients in second remission”
SLS in the first 10 minutes
From a reference price of $13.55 just before the headline, the stock was up 0.46% after one minute and up 2.03%, at $13.82, after 10 minutes. The move kept building after the first minute.
Other SLS headlines on November 20, 2026
- 16:01 ET: “SELLAS Life Sciences closes public offering of 13,269,231 shares and confirms full exercise of underwriters’ option” (-0.21% in 10 minutes)
Earlier SLS headlines and the measured reaction
MoveSurge measured three earlier SELLAS Life Sciences Group headlines with an attributed reaction between Aug 22, 2026 and Nov 19, 2026. The largest was +4.05% in 10 minutes, on Oct 28, 2026.
- Nov 19, 2026, 09:33 ET: “SELLAS Life Sciences prices a $150 million stock sale at a steep discount” (+1.01% in 10 minutes)
- Nov 19, 2026, 06:52 ET: “SELLAS Life Sciences prices a $150 million stock sale at a steep discount” (+3.06% in 10 minutes)
- Oct 28, 2026, 08:35 ET: “SELLAS Life Sciences says its Phase 3 REGAL trial of galinpepimut-S (GPS) for acute myeloid leukemia has reached its 80th event” (+4.05% in 10 minutes)
SELLAS Life Sciences Group at a glance
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Market value | $3.03 billion (as of Nov 20, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved SELLAS Life Sciences Group stock on November 20, 2026?
At 14:12:46 ET, this headline crossed: “Sellas Life Sciences says galinpepimut-S met the Phase 3 REGAL trial’s primary endpoint, reducing death risk by 41% in AML patients in second remission”. The stock rose 2.03% in the next 10 minutes.
How far did SLS move after the headline?
From $13.55 just before the headline to $13.82 10 minutes later, a +2.03% move.
What else has moved SLS stock recently?
The two largest measured reactions before November 20, 2026: Oct 28, 2026, SELLAS Life Sciences says its Phase 3 REGAL trial of galinpepimut-S (GPS) for acute myeloid leukemia has reached its 80th event (+4.05% in 10 minutes); Nov 19, 2026, SELLAS Life Sciences prices a $150 million stock sale at a steep discount (+3.06% in 10 minutes).
Sources
-
SLS headline and measured reaction, Nov 20, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Follow SLS live
The live feed pairs breaking headlines with measured price moves. Build a watchlist of stocks you own and choose whether matching news reaches your WhatsApp.
Open the live feed See portfolio WhatsApp alerts